A therapeutic dose and its pharmacokinetics of ropeginterferon Alfa-2b for hepatitis C treatment

A therapeutic dose and its pharmacokinetics of ropeginterferon Alfa-2b for hepatitis C treatment

Aim: Ropeginterferon alfa-2b is a novel mono-pegylated proline-interferon. Its biweekly dosing schema has demonstrated tolerability and clinical efficacy for treating chronic hepatitis in previous clinical studies. This trial evaluates the pharmacokinetics of 400 μg ropeginterferon alfa-2b in patien...

Full description

Bibliographic Details
Main Authors:	Ching-Chu Lo, Wan-Long Chuang, Hsing-Tao Kuo, Wei-Ming Chen, Albert Qin, Chan-Yen Tsai, Yi-Wen Huang, Chi-Yi Chen
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	Journal of the Formosan Medical Association
Subjects:	Clinical trial Hepatitis C virus genotype 2 Pegylated interferon
Online Access:	http://www.sciencedirect.com/science/article/pii/S0929664623003376

Similar Items

Ropeginterferon alfa‐2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy
by: Hsien‐Hong Lin, et al.
Published: (2021-08-01)

Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan
by: Jung-An Lin, et al.
Published: (2014-10-01)

Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers
by: Marisa Boff Costa, et al.
Published: (2018-01-01)

Pegylated Interferons and Their Use in Clinical Practice
by: Alpay AZAP, et al.
Published: (2003-12-01)

Using pegylated interferon alfa-2b and ribavirin to treat chronic hepatitis patients infected with hepatitis c virus genotype 1: are nonresponders and relapsers different populations?
by: Giovanni Faria Silva, et al.

Real-life results of sofosbuvir based therapy for patients with hepatitis C
by: D. G. Zhivitsa, et al.
Published: (2019-09-01)

Response factors to pegylated interferon-alfa/ribavirin treatment in chronic hepatitis C patients genotype 1b
by: Jovanović-Ćupić Snežana, et al.
Published: (2014-01-01)

Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT
by: Jaber Al-Ali, et al.
Published: (2012-03-01)

Treatment of human papillomavirus with peg-interferon alfa-2b and ribavirin
by: M.H.P. Pavan, et al.

A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin
by: Ching-Sheng Hsu, et al.
Published: (2014-10-01)

Pityriasis Rosea Associated with Pegylated Interferon Alfa and Ribavirin Treatment in a Patient with Chronic Hepatitis C
by: Rahmet Güner, et al.
Published: (2013-06-01)

Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature
by: Joan How, et al.
Published: (2020-07-01)

The sustained virologic response of nonresponder hepatitis C virus patients with retreatment
by: Sila Cetin Akhan, et al.
Published: (2011-01-01)

Antiviral Response across Genotypes after Treatment of Chronic Hepatitis B Patients with the Therapeutic Vaccine NASVAC or Pegylated Interferon
by: Mamun Al-Mahtab, et al.
Published: (2023-05-01)

The role of biochemical variations and genotype testing in determining the virological response of patients infected with hepatitis C virus
by: Abid Shoukat, et al.
Published: (2018-01-01)

Predictors of response to chronic hepatitis C treatment
by: Henrique Sergio Moraes Coelho, et al.
Published: (2010-01-01)

Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort
by: Ta-Wei Liu, et al.
Published: (2018-01-01)

An open, non-controlled clinical study to assess the efficacy and safety of the recombinant human alpha 2b pegylated interferon PEG-Heberon® plus ribavirin for the treatment of chronic hepatitis C virus infection in Cuban patients
by: Marlen I Castellanos-Fernández, et al.

HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b
by: Hui Ma, et al.
Published: (2016-01-01)

Add-on neurological benefits of antiviral therapy in HCV patients with chronic kidney disease — a nationwide cohort study
by: Ming-Shyan Lin, et al.
Published: (2017-08-01)

New approaches and therapeutic modalities for the treatment of patients with chronic hepatitis C
by: Markus Cornberg, et al.
Published: (2005-07-01)

The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B
by: Yi He, et al.
Published: (2022-07-01)

Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B
by: Zheng C, et al.
Published: (2019-04-01)

Predictors of treatment response in patients with hepatitis C 1b genotype
by: Brjalin Vadim, et al.
Published: (2013-12-01)

Hepatitis C-Related Cirrhosis with Sustained Prevention of Hepatocellular Carcinoma Recurrence by Long-Term Administration of Super-Low-Dose Peginterferon-Alpha 2b
by: Satoshi Mamori, et al.
Published: (2011-01-01)

Expression Pattern of Cytokines in Patients with Chronic Hepatitis B Receiving PEGinterferon Therapy
by: Chen SL, et al.
Published: (2023-05-01)

Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
by: Sundaram V, et al.
Published: (2016-06-01)

Early Experience of Sofosbuvir based Combination Therapy in “Real-Life” Cohort with Chronic Hepatitis-C Infection
by: Rajiv Mehta, et al.
Published: (2017-03-01)

Is Combined Bulevirtide and Pegylated Interferon Therapy for Chronic Hepatitis D Superior over Bulevirtide Monotherapy?
by: V. E. Syutkin, et al.
Published: (2020-09-01)

Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial
by: Lin YC, et al.
Published: (2019-04-01)

Cutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C
by: Elson Vidal Martins Jr., et al.
Published: (2009-11-01)

A Case Report of Ropeginterferon Alfa-2b for Polycythemia Vera during Pregnancy
by: Su-Yeon Bang, et al.
Published: (2023-03-01)

Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a
by: Rania M. El-Lababidi, et al.
Published: (2020-01-01)

CYTOPENIAS AND THEIR CORRECTION DURING ANTIVIRAL THERAPY OF CHRONIC HEPATITIS C IN PATIENTS WITH GENOTYPE 1
by: E. R. Manapova, et al.
Published: (2017-08-01)

Lymph node enlargement during combination therapy for chronic hepatitis C with pegylated interferon alpha and ribavirin: harmless reaction or harmful disease?
by: M Wilhelmi, et al.
Published: (2006-01-01)

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
by: Janine Hartl, et al.
Published: (2012-07-01)

Evaluation of the Results of Patients Treated By Pegylated Interferon Alpha Therapy
by: Çiğdem PAPİLA, et al.
Published: (2015-09-01)

Health-related quality of life in children with chronic hepatitis C
by: Ola Galal Ali Behairy
Published: (2016-09-01)

Cost comparison of treating chronic hepatitis C genotype one with pegylated interferons in Ukraine
by: Mandrik Olena, et al.
Published: (2015-01-01)

Side Effects of Therapy for Chronic Hepatitis C: High Incidence of Dermal and Mucosal Adverse Events
by: Hüseyin Şener BARUT, et al.
Published: (2010-03-01)